

PROVIDER QUICK POINTS

PROVIDER INFORMATION



February 8, 2023

Commercial Formulary Addition for Growth Hormone Therapeutic Class: Genotropin® (somatropin)

Effective **January 17, 2023**, the drug listed in the table below was added to formulary as a co-preferred brand growth hormone in response to the current Norditropin shortage. This co-preferred strategy will remain in place after the resolution of the Norditropin shortage.

Note: Genotropin is also subject to prior authorization. We are in the process of modifying existing prior authorizations in our claim system to allow members to receive Genotropin, in addition to Norditropin, to ensure a seamless transition when necessary.

Drug Name
Genotropin (somatropin) lyophilized powder for reconstitution and injection

Products Impacted

This applies to the commercial line of business.

Questions?

Please contact provider services at **(651) 662-5200** or **1-800-262-0820**.